Screener
Cytokinetics CYTK EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Cytokinetics’s reported figures.
Based on trailing twelve months.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
FAQ
- What is Cytokinetics's EBITDA margin?
- Cytokinetics (CYTK) reported EBITDA margin of -1,027.6% in Q2 2026.
- How has Cytokinetics's EBITDA margin changed year-over-year?
- Cytokinetics's EBITDA margin decreased by 63.9% year-over-year, from -627% to -1,027.6%.
- What is the long-term trend for Cytokinetics's EBITDA margin?
- Over 5 years (2020 to 2025), Cytokinetics's EBITDA margin has grown at a 32.9% compound annual growth rate (CAGR), from -165% to -683.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Cytokinetics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude